Travere Therapeutics names Bradley Campbell CEO effective Dec. 1, 2026

Bradley L. Campbell appointed president and CEO of Travere Therapeutics, effective Dec. 1, 2026. Outgoing CEO Eric Dube to remain until that date and then serve as executive advisor through Feb. 15, 2027.